Single-center observational study reveals clinical and echocardiographic changes after vutrisiran initiation in variant transthyretin amyloid cardiomyopathy, indicating real-world utility.
Background: Real-world data describing the clinical course after vutrisiran initiation in patients with variant transthyretin amyloid cardiomyopathy (ATTRv-CM) in non-endemic regions remain limited, particularly in Asian cohorts and in patients transitioning from patisiran. We evaluated preliminary real-world changes after vutrisiran initiation in patients with ATTRv-CM.
No takes yet. Share an insight, caveat, or question.
Zaizen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: